CWM
JAZZ icon

Compass Wealth Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Compass Wealth Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-500
Closed -$61.5K – 391
2023
Q4 		$61.5K Sell
500
-5,000
-91% -$624K 0.02% 230
2023
Q3 		$712K Sell
5,500
-335
-6% -$44.6K 0.22% 99
2023
Q2 		$723K Sell
5,835
-850
-13% -$114K 0.22% 99
2023
Q1 		$978K Sell
6,685
-300
-4% -$44.4K 0.31% 90
2022
Q4 		$1.11M Buy
+6,985
New +$1.02M 0.36% 80

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Compass Wealth Management's JAZZ Position: Q1 2024 in Review

Compass Wealth Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2024, closing a stake of 500 shares — an estimated $61.5K sold.

Compass Wealth Management first reported a position in JAZZ in Q4 2022 and held it in 5 quarters. The position peaked at $1.11M in Q4 2022. 480 funds tracked by Wall St. Rank hold JAZZ as of Q1 2024.

  • Compass Wealth Management reported no remaining Jazz Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Compass Wealth Management sold 500 Jazz Pharmaceuticals shares in Q1 2024, an estimated $61.5K.
  • Compass Wealth Management first reported a position in Jazz Pharmaceuticals in Q4 2022 and held it in 5 quarters.
  • Compass Wealth Management's Jazz Pharmaceuticals position peaked at $1.11M in Q4 2022.
  • 480 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2024.

Based on Compass Wealth Management's 13F filing for Q1 2024, filed 5 Apr 2024.